13th Annual Hematologic Malignancies Demystified: A Critical Appraisal of Data from 2020 

JANUARY 30  |  FEBRUARY 6


Complimentary CME Event

Explore the options in hematology and hematologic malignancies with these virtual meetings. Stay informed on new data with established agents and gain insight into the use of novel agents in your practice. Expert faculty will focus on updates from recent congresses and the latest clinically relevant data.

LETTER FROM THE CHAIR

Dear Colleagues,

Welcome to the 13th Annual Hematologic Malignancies Demystified: A Critical Appraisal of Data From 2020. We are pleased that you have chosen to attend this educational event. This meeting will provide a comprehensive review of the latest relevant findings reported at the American Society of Hematology (ASH) Annual Meeting and Exposition and other major congresses in 2020. I am confident that the presentations will provide you with a valuable update of practice-changing data that can be readily applied to the clinical management of patients with hematologic malignancies.

Best regards,

signature

Hagop M. Kantarjian, MD

The University of Texas
MD Anderson Cancer Center
Houston, Texas, United States
(Series Course Director)

CME/CE CREDITS AVAILABLE

PART I: [bold]3.0[/bold] | PART II: [bold]2.5[/bold] – [bold]CME/CE[/bold] 

LEARNING OBJECTIVES

Upon completion of this activity, learners will demonstrate: [list]Increased knowledge regarding the - Emerging clinical trial data for hematologic malignancies and disorders - Methods to assess treatment response in patients with hematologic malignancies or disorders - Treatment-related side effects in patients with hematologic malignancies or disorders[/list] [list]Greater confidence in their ability to individualize treatment in patients with hematologic malignancies or disorders [/list]

TARGET AUDIENCE

This educational activity is specifically designed for hematologists/oncologists, nurses, NPs, PAs, and other HCPs who are involved or interested in the management of patients with malignant and nonmalignant hematologic disorders.